Specifically, CD318 is also known to contribute to the proliferation of breast, lung, ovarian and prostate cancer cells via interacting with HER2 and receptor tyrosine kinases (RTKs), as well as the downstream proteins Ras, Src, and AKT. This evidence concerns the gene CDCP1 and prostate carcinoma.